Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2023 Apr 27;18(4):e0285003. doi: 10.1371/journal.pone.0285003

Enablers and barriers to effective HIV self-testing in the private sector among sexually active youths in Nigeria: A qualitative study using journey map methodology

Dennis Aizobu 1, Yusuf H Wada 1,*, Jennifer Anyanti 1, Godpower Omoregie 1, Boluwatife Adesina 1, Serah Malaba 2, Morghan Kabeer 3, Samuel Oyegunle 3, Akudo Ikpeazu 4, Omokhudu Idogho 1
Editor: Adetayo Olorunlana5
PMCID: PMC10138200  PMID: 37104495

Abstract

Background

HIV is a public health burden in Nigeria. HIV self-testing is one of the approaches to testing, which is the first of the 95:95:95 cascade of a coherent response to the epidemic. The ability to self-test HIV is influenced by various factors that can either serve as enablers or barriers. Exploring these enablers and barriers to the uptake of HIVST will help achieve optimal HIV self-testing and provide a deeper understanding of the HIVST kits users’ journey.

Objective

The purpose of the study was to identify enablers and barriers to the uptake of HIV self-testing among sexually active youth in Nigeria using journey map methodology.

Methods

We conducted a qualitative exploratory study between January 2021 to October 2021 to understand the journey map for taking up and using HIVST in the private health delivery systems which include the pharmacies and PPMVs. 80 youths in Lagos, Anambra and Kano states were interviewed using IDIs and in-person FGDs. Their responses were audio-recorded, transcribed and analyzed using a qualitative software package (Nvivo software).

Results

A journey map for taking up and effectively using HIVST using the private sector among sexually active youths using key enablers and barriers at the attract, purchase, use, confirmation, linkage, and reporting stage was developed. The major enablers among participants were privacy and confidentiality, bundling purchases with other health products, easy-to-use instructions, and past experience with other self-testing kits. The major barriers were fear of discrimination, big packaging, high price, lack of confidence from user error and fear of status disclosure.

Conclusions

Sexually active young people’s perspectives enhance our understanding of the barriers and enablers of using HIVST through the private sector. Optimizing the enablers such as improved confidentiality that may be seen in e-pharmacy, reducing barriers and factoring sexually young people’s perspectives will enhance the market and the uptake of HIVST towards ensuring sustainability and accelerating progress towards the 95-95-95 targets.

Background

HIV is a public health burden in Nigeria and worldwide. It remains devastating for adolescents and young adults aged 15–24 years, who bear a disproportionate burden of approximately 50% of all new HIV infections and 33% of persons living with HIV/AIDS globally [1]. In Nigeria, the prevalence of HIV is 1.4% among the general adult population, with about 1.9 million people living with HIV/AIDS as of 2018 [2]. Because of the tremendous threat HIV poses to public health, there remains a high proportion of key populations, especially sexually active young people, unaware of their HIV status [3]. These young people are at risk of exposing their sexual partners to new HIV infections, which threaten to undermine progress made in addressing the HIV epidemic. In contrast, studies have shown that the desire to be tested for HIV among adolescents in Africa is relatively high, with approximately two-thirds of untested adolescents desiring an HIV test [4].

Due to a lack of awareness of the importance of HIV testing, there is low initiation of anti-retroviral therapy (ART), which naturally hinders the success of global initiatives intending to eliminate HIV by 2030 [5]. Therefore, broadening screening opportunities by increasing access to HIV self-testing (HIVST) as part of a comprehensive method mix is a key strategy for reducing the prevalence and threat unknown HIV status poses in low-income countries. To help complement decreasing trends in HIV incidence, various countries, including Nigeria, have recently rolled out HIVST, especially those that use blood or saliva (oral HIV test) to test for HIV. The private sector delivers HIV prevention and care services to communities and serves as primary health delivery systems [3]. This includes the community pharmacies (CPs) and patent and proprietary medicine vendors (PPMVs) who provides HIV prevention services such as the HIVST kits and sexual and reproductive health (SRH) products and services such as condoms, lubricants and antiretrovirals [4]. However, due to low confidence from users in using HIVST, poor linkage to care, and low-risk perception in administering the HIVST, some young populations do not trust the accuracy of HIVST results [6]. These highlights the importance of documenting the barriers and enablers faced by young persons in the uptake of HIVST in Nigeria, especially with the involvement of private sector distribution to allow for self-care.

However, despite the large-scale programmatic approach to increase the prevalence of self-testing in Nigeria, multi-level barriers to the use of HIV testing among Nigerian youths have been reported at the individual (low perception of risk and fear), structural (lack of testing sites, stigma) and social (social support, service-related and limited peer support) level [510]. The major barrier to HIV testing and counselling cited by untested adolescents and young adults was fear, including parents’ reaction to a positive result, fear of needles, stigma/discrimination, AIDS-related illness and death [6, 11]. The involvement of private sector distribution of HIVST to allow for self-care requires key documentation of specific barriers and facilitators which could drive test demand, the usability of tests, and managing pricing to ensure broader access, mitigate transmission, and increase HIVST implementation through policy changes, programmatic approach, advocacy and research.

Furthermore, the research evidence regarding factors that enable and affect the uptake of HIVST, especially among youths globally and Nigeria in particular, remains limited. Only few studies have been able to explore the young people’s preferences for HIVST service delivery in Nigeria [7] and in sub-Saharan Africa [1214]. Therefore, in response to the above seemingly grim picture and to expand access to HIVST within the framework of informed choice, Society for Family Health (SFH) and partners: Population Services International (PSI) and National AIDS and STIs Control Program (NASCP), aimed to gather insights and identify gaps in HIV self-testing in Nigeria, and explore other factors which serve as enablers and barriers for the uptake of HIVST kits through the private sector. These will help to achieve optimal HIV self-testing and determine the journey of HIVST kits for users, providing a deeper understanding of the key moments along the journey: from attracting stage, purchase, use of test, confirmatory and linkage to prevention, care and treatment, where problems may occur.

Methods

Design

In this study, a descriptive qualitative study was used to explore insights on enablers and barriers to the uptake of HIVST kits. PSI and SFH conducted qualitative market research on HIV self-testing (HIVST) in the private health delivery systems (pharmacies and PPMVs) in Nigeria. The study was conducted in 3 PEPFAR priority states of Anambra, Lagos and Kano and represents the key geographical mapping in terms of HIV prevalence, unmet needs for HIV/AIDS treatment services and actual size estimation. This helps to understand the environment for users, how they interact with the private health delivery systems and the enablers and barriers to intervention on both the demand and supply aspects.

Journey map operation

The participant journey-map was adopted from studies [1517] and used to explore the pathway to identify potential pivot points, link encounters, understand perspectives that facilitate insights, promote proactive delivery of people-centered care, and improve study reliability. Our method, therefore, explored this approach to gain insights into the participants’ processes before taking up and using HIVST in private sector. This was subsequently used to create a narrative of the sexually active users’ thoughts and emotions, leading to visualization of their actions when taking up and using the HIVST kits.

In this study, we distilled the journey for taking up and using HIVST kits through the attract, purchase, and use stages and later diverges based on their perceived HIVST results. For those who receive a non-reactive result, they proceed to link through the HIV prevention continuum [1820]. They begin with a link to the HIV prevention services stage followed by retention in such services and later adherence to prevention interventions with repeated testing for HIV acquisition monitoring. While those who are perceived to have a reactive result proceed to the confirmatory testing, link to HIV care and treatment, and reporting stage. At each step, many factors inhibit their willingness and ability to use HIVST, which was reported.

Recruitment and participants selection

The study involved sexually active youths of different genders, residences, HIV status and past experience of using HIVST across Nigeria for FGDs and IDIs. We conducted 45 IDIs and 7 FGDs with 80 sexually active males and females across Anambra, Kano and Lagos states. IDIs and FGDs respondents were reassured that data that could potentially identify a person or location was anonymized and could not be traced back to them. Electronic data were password protected.

The recruitment of participants was carried out using clearly spelt-out eligibility criteria and a convenience sample drawn at random from a list of participants provided by community-based organizations (CBOs) and civil society organizations (CSOs) who fulfilled the criteria and were willing to write informed consent.

The inclusion criteria were: 1) sexually active young people between 18 and 29 years residing in urban or peri-urban settings in Nigeria that have either taken an HIVST or not. 2) willing and able to provide verbal informed consent and consent to an audio-recorded session.

Data collection

Data was collected through validated IDIs (S1 Appendix) and FGDs guides (S2 Appendix) that was developed after an extensive search of published literature [12, 14] and translated into the four dominant languages of Nigeria (English, Yoruba, Igbo, and Hausa). They were then validated through face and content validity to encourage the natural flow of conversation. The face validity was assessed by a team of experts from the Busara Centre for Behavioral Economics, SFH, PSI, Department of Public Health, Federal Ministry of Health, NACA and NASCP with relevant experience in the field of HIV. The content validity was also assessed by an independent team of experts (public health, epidemiologist, infectious diseases physician, and languages expert from the different languages used). The independent team of experts suggested some modifications including the flow and paraphrasing some sentences to be clear, unambiguous, essential and relevant. Thus, this gave us a final copy of our guide used in this research.

The project team from SFH and Busara who were part of the face validity team carried out the qualitative research and collected data in the four dominant language of Nigeria (English, Igbo, Hausa, and Yoruba) using the IDIs and FGDs guides. IDIs were done in English over the phone, while FGDs were conducted in-person for the sexually active youths using the four languages in the three states. We conducted gender-specific FGDs—one FGD was either all men or all women, but we mixed HIVST users and HIVST non-users. During both the IDIs and FGDs, we asked respondents open-ended questions regarding their opinions and perceptions of HIVST, and for IDIs with HIVST users, we asked questions about their past experiences with taking up and using HIVST kits. Triangulation of data from three sources (focus group transcripts, past experience detailing enablers and barriers, and individual questionnaires of sociodemographic) and interviews complemented involving individual prioritization of the barriers and facilitators to HIVST [21, 22].

Using information collected, we identified enablers and barriers to HIVST kit uptake and use, and then systematically mapped these enablers and barriers onto the journey map for taking up and using HIVST kits in the private sector, allowing us to clearly identify opportunities to leverage and challenges to overcome.

Data management and analysis

All data analysis were done based on Graneheium and Ludman system to assure trustworthiness [17]. Interviews were audio-recorded and transcribed verbatim. In-depth interviews (IDIs) and focus group discussions (FGDs) were audio-recorded, transcribed, and translated into English. Thematic analysis (TA) was used to analyse and code the data using a qualitative software package—Nvivo. Using information from the IDIs and FGDs, we identified enablers and barriers to taking up and using HIVST.

Ethical considerations

This study was approved by the two ethical review committees, the National Health Research Ethics Committee of Nigeria (NHREC)–NHREC/01/01/2007-29/06/2021 and the Nigerian Institute of Medical Research (NIMR)–IRB/21/043. Permission was also sought from the study participants through written informed consent. This was done after the benefits and objectives of the study had been fully read by them and all clarifications provided. All research activities were conducted in accordance with the Declarations of Helsinki and other policies and regulations required by the ethical committees. All respondents consented to participate, and they were free to voluntarily withdraw at any time with no attraction of penalty at any time during the research.

Results

In total, 80 participants were enrolled in the study, with majority being male (55%), at the age range of 21–25 (43.8), single (92.4), educated at tertiary level (57.4) and living in urban areas (52.5) [See Table 1]. FGDs were of the same gender, but groups were a mix of peri-urban/urban residents, HIV status, and past experience with HIVST. Majority of the IDIs were from sexually active youths who reside in Lagos state (17) with 3 FGDs that had a good representation from the urban and peri-urban settings. Majority of these IDIs have used HIVST in the IDIs, while there was a mix of both users and non-users for the FGDs. Anambra and Kano states have the same IDIs (14 each) and FGDs (2 each) representing males and females, both urban and peri-urban residents, people living with HIV and HIV-negative persons and users of HIVST and non-users [Fig 1].

Table 1. Demographic characteristics of participants.

Demographic variable Category Frequency (n) Percentage (%)
Age 18–20 19 23.75
21–25 35 43.75
26–29 26 32.50
Total 80 100
Gender Male 44 55.00
Female 36 45.00
Total 80 100
Marital Status Single 74 92.50
Married 5 6.25
Divorced 1 1.25
Total 80 100
Highest educational level Primary education 5 6.25
Secondary education 29 36.25
Tertiary education 46 57.50
Total 80 100
Geographic distribution Urban 42 52.50
Peri urban 38 47.50
Total 100 100
Interviews FGDs 45 86.54
IDIs 7 13.46
Total 52 100

Fig 1. showing the demographic characteristic of FGDs and IDIs with sexually active males and females in Anambra, Lagos and Kano states of Nigeria.

Fig 1

Enablers and barriers to taking up and using HIVST in the private sector

Description of the sexually active young people journey map:

In this study, seven individual steps were mapped out in detail and then condensed into a single journey map. The steps are the attract, purchase, use, confirmation testing, link to HIV care and treatment, link to HIV prevention and reporting stage, which are all crucial in developing effective and sustainable HIV self-testing care.

Throughout the entire journey map:

Fig 2 shows the enablers and barriers for taking up and using HIVST Kits in the private sector at various stages. Most sexually active males and females from our participants were aware of the factors that put them at risk of HIV, and most possessed the self-awareness to know that their behavior may put them at risk. Key themes as stages were highlighted, which shows the major enablers and barriers at every important stage which might either undermine or enable the use of HIVST in the private sector.

Fig 2. Enablers and barriers to taking up and using HIVST kits in the private sector.

Fig 2

Enablers and barriers at the attract stage

The major enablers that attracted sexually active youths to take up and use HIVST were: influence from friends in the health sector, online/social media or print and radio advertisements, awareness of the need for HIV testing, privacy/confidentiality of testing at home, community sensitization with friends and curiosity on alternative ways of testing. While the barriers included fear of discrimination from buying kit in public, perceived lack of awareness among peers, fear of reactive result, low-risk perception among peers and avoiding being treated as sick.

Enabler: Privacy/confidentiality of testing at home

The key enabler, which almost all participant related to, was the privacy and confidentiality of testing at home. Participants were attracted to the idea of testing at home and in private, without any influence from external parties. So, no one would know they took the test, and they could keep their results to themselves.

“What really got my attention from the onset was the fact that you can do it at home without anybody knowing about your status, so it was easy to make the decision to take [the HIVST kit]."

- Male, Lagos, 25yrs, Peri-urban

Barrier: Fear of discrimination from buying kit in public

The majority of participants at the attracting stage were afraid of being judged for buying the kits at a pharmacy by people within the community. They said they either would not buy the kit at a pharmacy or would go to a pharmacy in a neighboring community.

“That [pharmacy] won’t be comfortable for me considering how most people in the society view PLWHIV as sexually promiscuous individuals. Also, there are occasions where I get to meet attendants who are not professional in keeping customers’ status confidential…."

Male, Anambra, 25yrs, Urban

Enablers and barriers at the purchase stage

The key enablers identified by the participants were purchase and use at customers’ convenience, bundling purchasing with other health purchases, privacy with face masks and COVID-19, habitually buying condoms at pharmacies, online pharmacies in urban areas, and limited hassle factors to obtain HIV testing services. Contrastingly, the barriers in the purchase stage of HIVST in the private sector highlighted by the majority of participants include the convenience of subsequent care at health center, lack of awareness that kits are sold at pharmacies, insincere and untrustworthy pharmacists, big packaging and high price.

Enabler: Bundling purchase with other health products

Participants said buying HIVST at a pharmacy would be convenient, as they usually buy other health products at pharmacies, which they can also purchase while buying HIVST.

“Yes, it is very convenient to buy [HIVST] from the pharmacy mainly because the pharmacy is a place where you can get medical products for general public consumption. Hospitals may not be easily accessible.

- Male, Anambra, 24yrs, Urban

Barrier: Price

Participants thought the kits were too expensive. They were willing to pay between 100–1,000 Naira (US$ 0.2–2) for the kit.

“Myself and a lot of others also complained of the cost of the kit and considered it quite expensive. We felt most young people may not be able to afford it."

- Male, Anambra, 28yrs, Peri-urban

Enablers and barriers at the use stage

Overall, the majority of the participants thought HIVST kits were easy to use. They reported major enablers of using HIVST as having easy and salient instructions, past experience with other self-test kits, support from close friends, self-confidence and self-efficacy, painlessness of oral-fluid-based tests, autonomy, and confidence in HIVST efficacy. The major barriers were lack of confidence in HIVST from user error, lack of counseling from healthcare professionals, lack of confidence in HIVST from unexpected results, skepticism of oral-fluid-based kits and perception of doctor’s abilities.

Enabler: Autonomy

Majorly all participants liked that they could use the test where and when they wanted.

“Seeing the kit gives me joy. At least I can do it on my own, do it for anybody. I can just do it at my house, even in my office. I can do it anywhere.

- Female, Kano, 29yrs, Peri-urban

Barrier: Lack of counseling from healthcare professional

Most participants lamented that when doctors administer an HIV test at a health facility, they comfort and counsel patients upon receiving their results. Self-testing in private does not offer these counseling services that are often inherent to testing at a health facility.

“It shows that it’s HIV, but what I heard from the doctors is that it is not the worstwhen I tested and it was confirmed that there is HIV, then I said AIDS, and he said no, it is HIV, and he said when I keep taking care of myself, I will be fine and ok."

- Female, Kano, 28yrs, Peri-urban

Enablers and barriers at the confirmatory testing stage

Participants knew they were supposed to go to the health facility for confirmatory testing should they receive a reactive HIVST result. The majority of them said that the major enablers for them at the confirmatory testing were that the HIVST had clear instructional materials, support from close friends or siblings, their perceptions of doctor’s abilities, seriousness of reactive results and perceived responsibilities of doctors. They also highlighted key barriers at the confirmatory testing stage that included a lack of salient instructions on the next steps, lack of follow-up from healthcare providers, delays caused by shock and denial, comfort with non-reactive results, and lack of money for transportation.

Enabler: Seriousness of reactive results

Participants who tested reactive trusted that the results were accurate and took the results seriously, and as a result, went for confirmatory testing. Several participants implied that it was clear that they needed to go for confirmatory testing upon receiving a reactive result.

“Of course, I went for confirmation. That is when they asked me to come back in the next 3 months."

- Male, Kano, 29yrs, Urban

Barrier: Delays caused by shock and denial

Some participants were in shock and denial over their HIVST results and waited up to two months to go for confirmatory testing.

“I felt ashamed of the result, so I didn’t want to go [for confirmatory testing]. I felt embarrassed. I felt that something could be changed through prayers."

- Female, Anambra, 21yrs, Peri-urban

Enablers and barriers at the link to HIV care and treatment stage

Many participants were able to seamlessly link to HIV care and treatment immediately after receiving the results from their confirmatory test. But they also reported that experiencing poor health, seamless linkage to care after confirmatory testing, and knowledgeable healthcare centers were the main enablers of HIVST in the private sector. The major barriers limiting the linkages to HIV care and treatment after using HIVST were delays caused by stress and embarrassment, perception of unfriendly healthcare staff, avoidance of being treated as sick and fear of status definition.

Enabler: Seamless linkage to care after confirmatory testing

After participants went to the hospital for confirmatory testing, they were started on treatment immediately and didn’t need to go back to the health center for another appointment. This process minimized drop-off.

“I went to a health facility [after using HIVST] and got a confirmation test and treatment.

- Male, Lagos, 21yrs, Urban

Barrier: Delays caused by stress and embarrassment

Positive results after confirmatory testing evoked strong emotions of stress and embarrassment, leading some to delay seeking care.

“I started since when I was told that I am [positive]. I cried and went home. It was [my friend], she took me to one hospital, we went there, and we were attended to. [They] welcomed me in a nice way. I was interviewed by a doctor, and he gave me medicine."

-Female, Kano, 28yrs, Peri-urban

Enablers and barriers at the link to HIV prevention stage

After receiving a non-reactive HIVST result, the vast majority of participants did not do anything. To most, a non-reactive result was validation that their HIV prevention methods were effective, and they thought their knowledge of HIV prevention was sufficient.

Enabler: Awareness of need for HIV prevention

Participants were aware of the adverse effects of the disease and were self-aware enough to know they may be at risk. As a result, they consciously sought information to protect themselves, either by abstaining or using condoms. Many of these participants have friends that work in the health sector and/or have attended sensitizations on HIV.

“I usually seek information. I usually browse on my phone, read books [about] prevention and all that, and I read that one of the preventive measures is condom. Once you are using condoms, although you are not fully assured because sometimes it can burst, but I believe it is the number 1 preventive measure.

- Female, Anambra, 25yrs, Peri-urban

Barrier: Perceived knowledge of HIV prevention strategies

After using HIVST and testing non-reactive, participants did not seek out HIV prevention strategies. Most participants use condoms, and some use PREP. Most assumed their strategies were effective or they already knew everything they needed to know about HIV prevention.

“No [I didn’t seek information on HIV prevention] because I am an adult, and I already know about HIV prevention.

- Female, Lagos, 25yrs, Urban

Enablers and barriers at the reporting stage

Many participants acknowledge the importance of reporting their HIVST results. Some said they would consider reporting their results to facilitate linkage to HIV prevention or treatment and care:

“I think potential benefits [of reporting HIVST results] is getting access to the prevention services like PrEP.

Although many participants recognized the importance of reporting, many said they would not report their HIVST results to anyone, largely due to issues with privacy and confidentiality. They did not want many people to know their HIV status.

As one respondent stated: “If my result was positive, I think the negative consequences [of reporting my results] could be losing confidentiality over my health status.

Enabler: Easy to link to HIV treatment/prevention

Participants thought the main benefit of reporting their results more widely to other entities besides their hospital/health center would be access to better prevention measures or more immediate access to treatment.

“Yes, because I reported a negative result, I think potential benefits getting access to the prevention services like PrEP.

- Male, Lagos, 28yrs, Peri-urban

Barrier: Concerns over data privacy

Participants were concerned about data privacy; if NGOs, healthcare facilities, and other organizations were careless about data privacy, someone could see their results.

“…if you carelessly keep it and somebody comes and finds it.

- Male, Kano, 29yrs, Urban

Insights into the enablers and barriers for non-users of HIVST

Our findings reported that the majority of participants who were classified as non-users said that they did not think they needed HIVST, nor were they aware of where they could acquire HIVST. They also reported that they might want support from a close friend or sibling to use HIVST.

They also reported a low-risk perception at the attracting stage, with non-users saying they have never used HIVST because it never occurred to them or they never thought they needed it.

At the purchase stage, the majority of the participants reported a lack of awareness that kits are sold at pharmacies which might hinder the use of the HIVST. These non-users were unaware that they could get HIVST at a pharmacy, but they would be open to buying the kits for 200–500 Naira. Similarly, the majority highlighted self-efficacy and self-confidence at the use stage. Non-users have experience with self-testing, namely pregnancy self-test kits, and they felt confident with following the instructions and administering the test. At the confirmatory stage, there was a strong perception of support from close friends or siblings. Majority stated that “if they tested reactive, they would first tell a close friend or family member”, then go for confirmatory testing. Perceived knowledge of HIV prevention strategies and seamless linkage to care after confirmatory testing were reported at the linkage to HIV prevention stage and HIV care and treatment stage, respectively. At the reporting stage, the majority reported a lack of knowledge on the next steps for non-reactive results.

Discussion

To the best of our knowledge, this is the first study that has reported on the enablers and barriers to the uptake and use of HIVST in Nigeria with a good representation of the key geographical regions using a journey map. This is also the first study that reported a comprehensive report on the journey map for taking up and using HIVST in the private sector among sexually active males and females in any country of the world. Furthermore, this study is also the first on HIVST among youths that segregated the barriers and enablers based on every stage (attracting stage, purchase, use, confirmatory testing, linkages to care, prevention, treatment and reporting) that are key to generate demand.

There are roughly 500,000 PLHIV in Nigeria who do not know their HIV status [1]. HIVST offers an innovative new way to provide high-risk populations with HIV testing services. Only a few pilot experiments on HIVST have been implemented in West African countries, such as our sample cohort, Nigeria [23]. Through our IDIs and FGDs with sexually active youths, we uncovered many in-depth insights on taking up and using HIVST in the private sector. At a high level, we found that youths see value in having access to reliable HIV testing services, such as HIVST, as they are well-informed about HIV and its risk factors, which they learned from HIV sensitizations organized by non-governmental organizations (NGOs) and health workers in their communities. Likewise, young people like the convenience, accessibility, discretion, autonomy and ease of using HIVST kits whenever and wherever they please. This is consistent with studies conducted among young populations in many sub-Saharan African countries [7, 12, 2325].

Our study finds out that young people showed high acceptability and preferred the private-driven model over the public-driven model in the provision of HIVST kits. The reasons attributed to these were due to high accuracy and access to high-quality of HIVST in the private facilities. This is consistent with a study which reported young people’s preference for HIVST in Nigeria [7, 26]. However, their study only reported young people preference to the private sector whereas ours reported on both preference and usability. Young people at each stage reported fear of discrimination, perceived lack of awareness, high pricing, status disclosure, linkages to counseling services as key concerns. For policymakers and regulators, it is essential that young people are interested in using HIVST. Confidentiality, out of pocket payment and information plays significant roles in their decision to buy HIVST kits. While this clearly shows a market for HIVST, the drivers are limited. There is a need to eliminate these social and psychological barriers and explore the opportunities that exist [14].

An interesting result from our study was that many young people preferred home-delivery, low-cost and value HIVST for providing greater discretion around their sexual debut at the attract stage. This is consistent with a study of young people in Malawi and Zambia [12]. For example, at the attract and purchase stage, there was also a high perceived risk of fear of discrimination from buying a kit in public and fear of reactive results or being judged as a sick person. This is an important issue that needs to be addressed, especially leveraging the use of online pharmacy services approved recently by the Pharmacists Council of Nigeria, which can drive the provision of home delivery self-testing kits at one’s convenience. Additionally, this has important implications for policy design and full optimization of not only HIVST opportunities but also the entire self-care policy drive in Nigeria.

Further, the scalable strategies for confirmation of their HIV status and linkages of HIV prevention, care and treatment need to be optimized and so much needed to maximize individual and public health benefits of HIVST [27]. Confidence in healthcare professionals also encourages young people to seek confirmatory testing after using HIVST, as youths trust healthcare professionals to properly administer a confirmatory HIV test and provide them with adequate HIV treatment and care. However, high perceived trust in health care professionals, such as doctors, also posed a barrier to HIVST uptake and use in the private sector. Similarly, HIV testing at the health facility is free, and many youths think the price of HIVST at the pharmacy is unaffordable. Besides being too expensive, youths are reluctant to purchase HIVST at a pharmacy or PPMV because they don’t trust the pharmacist or PPMV owner to keep their purchase confidential, and they would not want other customers to see what they’re buying. This implies that young people are willing to pay if they believe the prices, they pay signal more quality of care and services, such as the provision of accurate information, and if they trust their doctors. These findings are in line with many reported studies which shows that willingness to purchase and low ability to pay for HIVST kits are associated with quality of care and unique value effect of the product across sub-Saharan Africa [12, 2835].

Therefore, evidence of new delivery models, such as social business marketing on affordable and effective HIVST delivery models for increasing testing coverage among key populations such as young people, underserved populations and high-risk populations, are necessary for country decision-making in countries like Nigeria [21]. The social business enterprise model through a total market approach has been used for many reproductive health products, such as condoms, to expand access to high-quality and low-cost products to fulfil important needs of the underserved population. Additionally, the majority of HIVST users and non-users reported that self-efficacy and self-confidence at the use stage were key enablers of HIVST. This is consistent for HIVST and other self-testing kits, such as pregnancy self-test kits, which they felt confident with following the instructions and administering the test. It would also be important to expand this instruction to other dominants language such as Hausa, Igbo and Yoruba for a wider audience coverage.

Limitation

Our study was a qualitative, multi-centered study with the largest sample size among similar studies done in Africa with similar objectives. However, it does have limitations that might be subject to social desirability bias. Our methodological approach led to a few limitations that affected the interpretation and application of our results. We used convenience sampling to recruit sexually active participants, which may introduce bias. However, we took steps to minimize sampling bias by the use of multiple sites, using indirect questions, random sampling from pool of participants presented, inclusion of both the users and non-users and ensuring the sufficient sample size to enable the applicability of results. Many sexually active males and females were recruited from HIV prevention, care, and treatment programs and other existing HIVST programs. As such, they were aware of HIV risk factors, testing methods, and prevention strategies, and as a result, more likely to recognize the need for HIV testing. Their knowledge and perceptions are reflected in the answers they provided during the IDIs and FGDs and may not represent the average sexually active young person in Nigeria, who is not currently involved in any HIV or HIVST program.

Conclusion

This paper offers an overview of the journey map for taking up and using HIVST in the private sector. Optimizing the enablers, such as improved confidentiality, that may be seen in e-pharmacy, reducing barriers and factoring sexually young people’s perspectives will enhance the market and the uptake of HIVST towards ensuring sustainability and accelerating progress towards the 95-95-95 targets. This also impacts health-seeking behaviors, which for HIV has significant ramifications on outcomes on prevention, treatment and viral suppression due to the rapid progression of the disease. Furthermore, an important next step for research will be to explore the possibilities of using an online pharmacy model to address some of these barriers, and the possible economic cost analysis of HIVST distribution modalities, such as social marketing models and secondary distribution, among others. This would enable efficient programs to be formulated to provide linkages with the supply chain, understanding the true picture, cause and stakeholders for key policy actions, advocacy and grow the market through sustainable financing.

Supporting information

S1 Appendix. IDI guide, sexually active males and females.

(DOCX)

S2 Appendix. FGD guide, sexually active males and females.

(DOCX)

Data Availability

Data cannot be shared publicly because of the nature of the study and national ethical restrictions on data which includes potential identifiable voice and names through the FGDs and IDIs and contain/identify potential sensitive information of the stakeholders, identify HIVST products which have influence on the participants safety. They were also assured that data will only be anonymously analyzed and also shared only on reasonably request as approved on the research protocol. Data are available from Society for Family Health Institutional Data Access for researchers who meet the criteria for access to confidential information through a non-author point of contact email info@sfhnigeria.org or through the corresponding author email hwada@sfhnigeria.org."

Funding Statement

This study was possible by the generous support of Children’s Investment Fund Foundation (CIFF) - Global Fund partnership through the Population Services International (PSI). The contents herein are the sole responsibility of the authors and do not necessarily reflect the views of SFH, PSI or CIFF. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.

References

  • 1.UNAIDS (2015). All in to #End Adolescent AIDS. UNAIDS website: http://www.unaids.org/sites/default/files/media_asset/20150217_ALL_IN_brochure.pdf [Accessed June 1st, 2022]
  • 2.UNAIDS (2019). Nigeria National HIV/AIDS Indicator and Impact Survey (NAIIS) https://www.unaids.org/en/resources/presscentre/pressreleaseandstatementarchive/2019/march/20190314_nigeria [Accessed June 1st, 2022]
  • 3.Ehrhardt AA, Sawires S, McGovern T, Peacock DWM. Gender, empowerment, and health: what is it? How does it work? J Acquir Immune Defic Syndr. 2009;51(3):96. doi: 10.1097/QAI.0b013e3181aafd54 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Asaolu IO, Gunn JK, Center KE, Koss MP, Iwelunmor JI, Ehiri JE. Predictors of HIV testing among youth in sub-Saharan Africa: a cross-sectional study. PLoS One. 2016;11(10):e0164052. doi: 10.1371/journal.pone.0164052 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.UNAIDS. 90-90-90 An ambitious treatment target to help end the AIDS epidemic. Geneva: 2014. [Google Scholar]
  • 6.Sam-Agudu NA, Folayan MO, Ezeanolue EE. Seeking wider access to HIV testing for adolescents in sub-Saharan Africa. Pediatr Res. 2016;79(6):838–45.\ doi: 10.1038/pr.2016.28 [DOI] [PubMed] [Google Scholar]
  • 7.Obiezu-Umeh C., Gbajabiamila T., Ezechi O. et al. Young people’s preferences for HIV self-testing services in Nigeria: a qualitative analysis. BMC Public Health 21, 67 (2021). 10.1186/s12889-020-10072-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Sedlander E., Long M.W., Mohanty S. et al. Moving beyond individual barriers and identifying multi-level strategies to reduce anemia in Odisha India. BMC Public Health 20, 457 (2020). 10.1186/s12889-020-08574-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Ibrahim M, Ipadeola O, Adebayo S, Fatusi A. Socio-demographic determinants of HIV counseling and testing uptake among young people in Nigeria. Int J Prev Treatment. 2013;2(3):23–31. [Google Scholar]
  • 10.Oshi SN, Ezugwu FO, Oshi DC, Dimkpa U, Korie FC, Okperi BO. Does selfperception of risk of HIV infection make the youth to reduce risky behaviour and seek voluntary Counselling and testing services? A case study of Nigerian youth. J Soc Sci. 2018;14(2):201–3. [Google Scholar]
  • 11.World Health Organization. The Voices, Values and Preference of Adolescents on HIV Testing and Counselling, 2013. http://www.who.int/iris/bitstream/10665/95143/1/WHO_HIV_2013.135_eng.pdf.
  • 12.Indravudh PP, Sibanda EL, d’Elbee M, Kumwenda MK, Ringwald B, Maringwa G, et al. ‘I will choose when to test, where I want to test’: investigating young people’s preferences for HIV self-testing in Malawi and Zimbabwe. AIDS. 2017; 31(Suppl 3):S203–12. 21. doi: 10.1097/QAD.0000000000001516 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Harichund C, Moshabela M. Acceptability of HIV self-testing in sub-Saharan Africa: scoping study. AIDS Behav. 2018;22(2):560–8. doi: 10.1007/s10461-017-1848-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Tonen-Wolyec S, Mbopi-Kéou F-X, Koyalta D, Filali M, Batina-Agasa S, Bélec L. Human immunodeficiency virus self-testing in adolescents living in subSaharan Africa: an advocacy. Niger Med J. 2019;60(4):165–8. doi: 10.4103/nmj.NMJ_75_19 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Ciria-Suarez L, Jiménez-Fonseca P, Palacín-Lois M, Antoñanzas-Basa M, Férnández-Montes A, Manzano-Fernández A, et al. Ascertaining breast cancer patient experiences through a journey map: A qualitative study protocol. PLoS One. 2020. Dec 21;15(12):e0244355. doi: 10.1371/journal.pone.0244355 Update in: PLoS One. 2021 Sep 22;16(9):e0257680. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.McCarthy S, O’Raghallaigh P, Woodworth S, Lim YY, Kenny LC, Adam F. Embedding the Pillars of Quality in Health Information Technology Solutions Using "Integrated Patient Journey Mapping" (IPJM): Case Study. JMIR Hum Factors. 2020. Sep 17;7(3):e17416. doi: 10.2196/17416 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Graneheim UH, Lundman B. Qualitative content analysis in nursing research: concepts, procedures and measures to achieve trustworthiness. Nurse Educ Today. 2004. Feb;24(2):105–12. doi: 10.1016/j.nedt.2003.10.001 [DOI] [PubMed] [Google Scholar]
  • 18.McNairy A, Margaret L, and El-Sadr Wafaa M. “A paradigm shift: focus on the HIV prevention continuum.” Clinical infectious diseases: an official publication of the Infectious Diseases Society of America vol. 59 Suppl 1,Suppl 1 (2014): S12–5. doi:10.1093/cid/ciu251. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.B. Horn Tim et al. “Towards an integrated primary and secondary HIV prevention continuum for the United States: a cyclical process model.” Journal of the International AIDS Society vol. 19,1 21263. 17 Nov. 2016, doi: 10.7448/IAS.19.1.21263 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Aizobu D, Idogho O, Anyanti J, Omoregie G, Adesina B, Kabeer M, et al. Stakeholders’ perception of a total market approach to HIV self-testing (HIVST) for the private sector in Nigeria. BMC Public Health. 2023. Mar 23;23(1):550. doi: 10.1186/s12889-023-15352-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.University of California, San Francisco (2008). HIV Data Triangulation Resource Guide: Synthesis of Results from Multiple Data Sources for Evaluation and Decision-making. WHO, UNAIDS, Global Fund. https://globalhealthsciences.ucsf.edu/sites/globalhealthsciences.ucsf.edu/files/pub/gsi-tri-oms-hiv-triangulation-guide.pdf [Accessed November 10th, 2022]
  • 22.Boehme AK, Davies SL, Moneyham L, Shrestha S, Schumacher J, Kempf MC. A qualitative study on factors impacting HIV care adherence among postpartum HIV-infected women in the rural southeastern USA. AIDS Care. 2014;26(5):574–81. doi: 10.1080/09540121.2013.844759 Epub 2013 Oct 14. PMID: . [DOI] [PubMed] [Google Scholar]
  • 23.Rouveau N., Ky-Zerbo O., Boye S. et al. Describing, analysing and understanding the effects of the introduction of HIV self-testing in West Africa through the ATLAS programme in Côte d’Ivoire, Mali and Senegal. BMC Public Health 21, 181 (2021). 10.1186/s12889-021-10212-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Hatzold K, Gudukeya S, Mutseta MN, Chilongosi R, Nalubamba M, Nkhoma C, et al. HIV selftesting: breaking the barriers to uptake of testing among men and adolescents in sub-Saharan Africa, experiences from STAR demonstration projects in Malawi, Zambia and Zimbabwe. J Int AIDS Soc. 2019;22(S1): e25244. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Hector J, Davies M-A, Dekker-Boersema J, Aly MM, Abdalad CCA, Langa EBR, et al. Acceptability and performance of a directly assisted oral HIV self-testing intervention in adolescents in rural Mozambique. PLoS One. 2018;13(4):e0195391. doi: 10.1371/journal.pone.0195391 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Indravudh, Pitchaya P Choko, Augustine T.; Corbett, Elizabeth L Scaling up HIV self-testing in sub-Saharan Africa: a review of technology, policy and evidence, Current Opinion in Infectious Diseases: February 2018—Volume 31—Issue 1—p 14–24 doi: 10.1097/QCO.000000000000042627. [DOI] [PMC free article] [PubMed]
  • 27.Asiimwe S, Oloya J, Song X, et al. Accuracy of un-supervised versus provider-supervised self-administered HIV testing in Uganda: a randomized implementation trial. AIDS Behav 2014; 18:2477–2484. doi: 10.1007/s10461-014-0765-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Knight L, Taegtmeyer M, et al. HIV self-testing could ‘revolutionize testing in South Africa, but it has got to be done properly’: perceptions of key stakeholders. PLoS One 2015; 10:e0122783. doi: 10.1371/journal.pone.0122783 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Knight L, Makusha T, Lim J, et al. I think it is right’: a qualitative exploration of the acceptability and desired future use of oral swab and finger-prick HIV self-tests by lay users in KwaZulu-Natal, South Africa. BMC Res Notes 2017; 10:486 doi: 10.1186/s13104-017-2810-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Pant Pai N, Behlim T, Abrahams L, et al. Will an unsupervised self-testing strategy for HIV work in healthcare workers of South Africa? A cross sectional pilot feasibility study. PLoS One 2013; 8:e79772. doi: 10.1371/journal.pone.0079772 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Kelvin EA, Cheruvillil S, Christian S, et al. Choice in HIV testing: the acceptability and anticipated use of a self-administered at-home oral HIV test among South Africans. Afr J AIDS Res 2016; 15:99–108. doi: 10.2989/16085906.2016.1189442 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Burke VM, Nakyanjo N, Ddaaki W, et al. HIV self-testing values and preferences among sex workers, fishermen, and mainland community members in Rakai, Uganda: a qualitative study. PLoS One 2017; 12:e0183280. doi: 10.1371/journal.pone.0183280 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Mugo PM, Micheni M, Shangala J, et al. Uptake and acceptability of oral HIV self-testing among community pharmacy clients in Kenya: a feasibility study. PLoS One 2017; 12:e0170868 doi: 10.1371/journal.pone.0170868 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Kurth AE, Cleland CM, Chhun N, et al. Accuracy and acceptability of oral fluid HIV self-testing in a general adult population in Kenya. AIDS Behav 2016; 20:870–879. doi: 10.1007/s10461-015-1213-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Mokgatle MM, Madiba S. High acceptability of HIV self-testing among technical vocational education and training college students in Gauteng and North West province: what are the implications for the scale up in South Africa? PLoS One 2017; 12:e0169765. doi: 10.1371/journal.pone.0169765 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Jamie Males

3 Nov 2022

PONE-D-22-23769Enablers and Barriers to Effective HIV Self-testing in the Private Sector among Sexually active youths in Nigeria: A Qualitative Study using Journey Map methodologyPLOS ONE

Dear Dr. Hassan Wada,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please respond carefully to all of the points the reviewers have raised when preparing your revision.

Please submit your revised manuscript by Dec 17 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Jamie Males

Editorial Office

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf   

2. Thank you for stating the following in the Acknowledgments Section of your manuscript:

“This study was possible by the generous support of Children’s Investment Fund Foundation (CIFF) - Global Fund partnership through the Population Services International (PSI). The contents herein are the sole responsibility of the authors and do not necessarily reflect the views of SFH, PSI or CIFF. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. We appreciate all members of the SFH SHIPS team, NACA, and ANAYD for their support during the data collection. We are most grateful to all the participants who took part in the study.”

We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form.

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows:

“This study was possible by the generous support of Children’s Investment Fund Foundation (CIFF) - Global Fund partnership through the Population Services International (PSI). The contents herein are the sole responsibility of the authors and do not necessarily reflect the views of SFH, PSI or CIFF. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. “

Please include your amended statements within your cover letter; we will change the online submission form on your behalf

3. Thank you for stating the following in your Competing Interests section:  

“None”

Please complete your Competing Interests on the online submission form to state any Competing Interests. If you have no competing interests, please state "The authors have declared that no competing interests exist.", as detailed online in our guide for authors at http://journals.plos.org/plosone/s/submit-now

 This information should be included in your cover letter; we will change the online submission form on your behalf.

4. We note that you have stated that you will provide repository information for your data at acceptance. Should your manuscript be accepted for publication, we will hold it until you provide the relevant accession numbers or DOIs necessary to access your data. If you wish to make changes to your Data Availability statement, please describe these changes in your cover letter and we will update your Data Availability statement to reflect the information you provide.

5. Please ensure that you refer to Figure 1 in your text as, if accepted, production will need this reference to link the reader to the figure.

6. We note that Figure 1 in your submission contain [map/satellite] images which may be copyrighted. All PLOS content is published under the Creative Commons Attribution License (CC BY 4.0), which means that the manuscript, images, and Supporting Information files will be freely available online, and any third party is permitted to access, download, copy, distribute, and use these materials in any way, even commercially, with proper attribution. For these reasons, we cannot publish previously copyrighted maps or satellite images created using proprietary data, such as Google software (Google Maps, Street View, and Earth). For more information, see our copyright guidelines: http://journals.plos.org/plosone/s/licenses-and-copyright.

 We require you to either (1) present written permission from the copyright holder to publish these figures specifically under the CC BY 4.0 license, or (2) remove the figures from your submission:

    a. You may seek permission from the original copyright holder of Figure(s) [#] to publish the content specifically under the CC BY 4.0 license. 

We recommend that you contact the original copyright holder with the Content Permission Form (http://journals.plos.org/plosone/s/file?id=7c09/content-permission-form.pdf) and the following text:

“I request permission for the open-access journal PLOS ONE to publish XXX under the Creative Commons Attribution License (CCAL) CC BY 4.0 (http://creativecommons.org/licenses/by/4.0/). Please be aware that this license allows unrestricted use and distribution, even commercially, by third parties. Please reply and provide explicit written permission to publish XXX under a CC BY license and complete the attached form.”

Please upload the completed Content Permission Form or other proof of granted permissions as an "Other" file with your submission.

In the figure caption of the copyrighted figure, please include the following text: “Reprinted from [ref] under a CC BY license, with permission from [name of publisher], original copyright [original copyright year].”

    b. If you are unable to obtain permission from the original copyright holder to publish these figures under the CC BY 4.0 license or if the copyright holder’s requirements are incompatible with the CC BY 4.0 license, please either i) remove the figure or ii) supply a replacement figure that complies with the CC BY 4.0 license. Please check copyright information on all replacement figures and update the figure caption with source information. If applicable, please specify in the figure caption text when a figure is similar but not identical to the original image and is therefore for illustrative purposes only.

The following resources for replacing copyrighted map figures may be helpful:

 USGS National Map Viewer (public domain): http://viewer.nationalmap.gov/viewer/

The Gateway to Astronaut Photography of Earth (public domain): http://eol.jsc.nasa.gov/sseop/clickmap/

Maps at the CIA (public domain): https://www.cia.gov/library/publications/the-world-factbook/index.html and https://www.cia.gov/library/publications/cia-maps-publications/index.html

NASA Earth Observatory (public domain): http://earthobservatory.nasa.gov/

Landsat: http://landsat.visibleearth.nasa.gov/

USGS EROS (Earth Resources Observatory and Science (EROS) Center) (public domain): http://eros.usgs.gov/#

Natural Earth (public domain): http://www.naturalearthdata.com/

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: N/A

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: No

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: No

Reviewer #2: No

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: “Enablers and Barriers to Effective HIV Self-testing in the Private Sector among Sexually active youths in Nigeria: A Qualitative Study using Journey Map methodology” presents qualitative data from in-depth interviews and focus group discussions with 80 participants involved in market research in Lagos, Anambra, and Kano states from January 2021 to October 2021. Although this is an important area of investigation, the current writing is weak and has numerous grammatical errors, making portions of the manuscript difficult to comprehend. I strongly recommend utilizing the services of a copyeditor to enhance clarity. Some of my questions, concerns, and suggestions are as follows:

1. Abstract – The opening sentences in the objectives and methods are very similar. Please revise the objectives to specify that the purpose of this qualitative study was to identify enablers and barriers to the uptake of HIV self-testing among sexually active youth in Nigeria using journey map methodology.

2. Introduction – It would be helpful to clarify the meaning of “effective self-testing in the private sector” in the introduction. Does this refer to the distribution of HIV self-testing kits by manufacturers or pharmacies? Would the kits be available for free, or would they have to be purchased? Is this already being done in any states in Nigeria? What types of HIV self-tests are commercially available – oral fluid or finger-stick blood or both?

3. Methods – How were participants recruited? What were the inclusion and exclusion criteria?

4. Methods – Please provide a brief description (2-3 sentences) of the journey map methodology along with appropriate citations for the benefit of readers unfamiliar with this approach.

5. Results – It would be helpful to include a table summarizing the demographic characteristics of the 80 participants. Figure 1 does include their geographic distribution, but no figures have been presented. For example, how many men and women were in the sample? What was the age range? How many lived in urban and peri-urban areas?

6 Discussion – Is there a reason why the results might not be subject to social desirability bias?

Reviewer #2: The authors should streamline their manuscript to focus on Enablers and Barriers to effective HIV self-testing in Private sector. Currently the manuscript is disorganized with irrelevant information,which doesn't address the enablers/barriers to effective HIVST. Also the authors should explicitly describe how was the Journey Map method operationalized in this study so a reader can follow. The author should also highlight what was the role of the private sector in this study. Did the author want to describe the role private health delivery systems? The author should use scientific writing, currently the manuscript is full of irrelevant words which doesn't add any value to the paper. The authors should check for grammar and spellings before their next submission.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2023 Apr 27;18(4):e0285003. doi: 10.1371/journal.pone.0285003.r002

Author response to Decision Letter 0


16 Jan 2023

Society for Family Health,

No. 8 Port Harcourt Crescent

Abuja, Nigeria

November 15th 2022

The Editor-in-Chief,

Editorial Office

PLOS ONE

Dear Editor-in-Chief,

We thank the academic editor and the reviewers for the comments to improve on our manuscript [PONE-D-22-23769]. Please see below our itemized point-by-point responses has been highlighted. Moreover, in the revised manuscript, all changes have been tracked to indicate the revised sections. We would be happy to clarify any aspect of our responses if needed.

Best Regards,

Yusuf H. Wada

Corresponding Author

hwada@sfhnigeria.org

Academic Editor

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

We thank the academic editor for this comment, we have updated the manuscript with the PLOS ONE’s style requirement as advised.

2. Thank you for stating the following in the Acknowledgments Section of your manuscript:

“This study was possible by the generous support of Children’s Investment Fund Foundation (CIFF) - Global Fund partnership through the Population Services International (PSI). The contents herein are the sole responsibility of the authors and do not necessarily reflect the views of SFH, PSI or CIFF. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. We appreciate all members of the SFH SHIPS team, NACA, and ANAYD for their support during the data collection. We are most grateful to all the participants who took part in the study.”

We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form.

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows:

“This study was possible by the generous support of Children’s Investment Fund Foundation (CIFF) - Global Fund partnership through the Population Services International (PSI). The contents herein are the sole responsibility of the authors and do not necessarily reflect the views of SFH, PSI or CIFF. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. “

Please include your amended statements within your cover letter; we will change the online submission form on your behalf

We thank the academic editor for this. This have been addressed.

3. Thank you for stating the following in your Competing Interests section:

“None”

Please complete your Competing Interests on the online submission form to state any Competing Interests. If you have no competing interests, please state "The authors have declared that no competing interests exist.", as detailed online in our guide for authors at http://journals.plos.org/plosone/s/submit-now

This information should be included in your cover letter; we will change the online submission form on your behalf.

We thank the academic editor for this. This have been addressed.

4. We note that you have stated that you will provide repository information for your data at acceptance. Should your manuscript be accepted for publication, we will hold it until you provide the relevant accession numbers or DOIs necessary to access your data. If you wish to make changes to your Data Availability statement, please describe these changes in your cover letter and we will update your Data Availability statement to reflect the information you provide.

We thank the academic editor for this.

5. Please ensure that you refer to Figure 1 in your text as, if accepted, production will need this reference to link the reader to the figure.

We thank the academic editor for this. We have changed in figure to a new one as reflected in the fig 1 uploaded.

6. We note that Figure 1 in your submission contain [map/satellite] images which may be copyrighted. All PLOS content is published under the Creative Commons Attribution License (CC BY 4.0), which means that the manuscript, images, and Supporting Information files will be freely available online, and any third party is permitted to access, download, copy, distribute, and use these materials in any way, even commercially, with proper attribution. For these reasons, we cannot publish previously copyrighted maps or satellite images created using proprietary data, such as Google software (Google Maps, Street View, and Earth). For more information, see our copyright guidelines: http://journals.plos.org/plosone/s/licenses-and-copyright.

We require you to either (1) present written permission from the copyright holder to publish these figures specifically under the CC BY 4.0 license, or (2) remove the figures from your submission:

a. You may seek permission from the original copyright holder of Figure(s) [#] to publish the content specifically under the CC BY 4.0 license.

We recommend that you contact the original copyright holder with the Content Permission Form (http://journals.plos.org/plosone/s/file?id=7c09/content-permission-form.pdf) and the following text:

“I request permission for the open-access journal PLOS ONE to publish XXX under the Creative Commons Attribution License (CCAL) CC BY 4.0 (http://creativecommons.org/licenses/by/4.0/). Please be aware that this license allows unrestricted use and distribution, even commercially, by third parties. Please reply and provide explicit written permission to publish XXX under a CC BY license and complete the attached form.”

Please upload the completed Content Permission Form or other proof of granted permissions as an "Other" file with your submission.

In the figure caption of the copyrighted figure, please include the following text: “Reprinted from [ref] under a CC BY license, with permission from [name of publisher], original copyright [original copyright year].”

b. If you are unable to obtain permission from the original copyright holder to publish these figures under the CC BY 4.0 license or if the copyright holder’s requirements are incompatible with the CC BY 4.0 license, please either i) remove the figure or ii) supply a replacement figure that complies with the CC BY 4.0 license. Please check copyright information on all replacement figures and update the figure caption with source information. If applicable, please specify in the figure caption text when a figure is similar but not identical to the original image and is therefore for illustrative purposes only.

The following resources for replacing copyrighted map figures may be helpful:

USGS National Map Viewer (public domain): http://viewer.nationalmap.gov/viewer/

The Gateway to Astronaut Photography of Earth (public domain): http://eol.jsc.nasa.gov/sseop/clickmap/

Maps at the CIA (public domain): https://www.cia.gov/library/publications/the-world-factbook/index.html and https://www.cia.gov/library/publications/cia-maps-publications/index.html

NASA Earth Observatory (public domain): http://earthobservatory.nasa.gov/

Landsat: http://landsat.visibleearth.nasa.gov/

USGS EROS (Earth Resources Observatory and Science (EROS) Center) (public domain): http://eros.usgs.gov/#

Natural Earth (public domain): http://www.naturalearthdata.com/

[Note: HTML markup is below. Please do not edit.]

We thank the academic editor for this. We have provided a replacement map as directed.

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Partly

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: N/A

Reviewer #2: Yes

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: No

Reviewer #2: Yes

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: No

Reviewer #2: No

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1:

“Enablers and Barriers to Effective HIV Self-testing in the Private Sector among Sexually active youths in Nigeria: A Qualitative Study using Journey Map methodology” presents qualitative data from in-depth interviews and focus group discussions with 80 participants involved in market research in Lagos, Anambra, and Kano states from January 2021 to October 2021. Although this is an important area of investigation, the current writing is weak and has numerous grammatical errors, making portions of the manuscript difficult to comprehend. I strongly recommend utilizing the services of a copyeditor to enhance clarity. Some of my questions, concerns, and suggestions are as follows:

We thank the reviewer 1 for this comment. The manuscript has been edited by a copyeditor to enhance clarity as advised.

1. Abstract – The opening sentences in the objectives and methods are very similar. Please revise the objectives to specify that the purpose of this qualitative study was to identify enablers and barriers to the uptake of HIV self-testing among sexually active youth in Nigeria using journey map methodology.

We thank the reviewer 1 for this comment, the objectives of the study have been rephrased as advised.

2. Introduction – It would be helpful to clarify the meaning of “effective self-testing in the private sector” in the introduction. Does this refer to the distribution of HIV self-testing kits by manufacturers or pharmacies? Would the kits be available for free, or would they have to be purchased? Is this already being done in any states in Nigeria? What types of HIV self-tests are commercially available – oral fluid or finger-stick blood or both?

We thank reviewer 1 for this comment. Within the context of this manuscript, effective self-testing in the private sector means the effective utilization of HIVST kits and linkage to sexual reproductive health services and to HIV prevention by pharmacies (who are only approved to provide those services), while the distribution of HIV self-testing at the retail level is by the pharmacies. This is in line with the revised National HIV and AIDS strategic framework 2019-2021 as a priority policy and porgarmmatic approach to HIV response in Nigeria (NACA. Revised National HIV and AIDS Strategic Framework 2019-2021. Abuja: Nigeria. National Agency for Control of AIDS; 2019). We also updated the manuscript to reflect the context of effective self-testing in the private sector. The kits would have to be purchased at the pharmacies and currently being sold in different pharmacies in Lagos, FCT, Rivers, Akwa-Ibom, Anambra and other states in Nigeria. Therefore, this pilot study finding is set to to provide evidencebased date and influence government, policy makers, donors and business/investment case to scale up free, incentivized or subsidized HIVST kits and for successful future HIVST campaigns in the private sector. There are many types of HIVST kits commercially available in Nigeria such as OraQuick (oral-fluid based), Mylan (blood-based), Insti (blood-based), DrGregs (blood based) and 3-H viral blood check (blood-based). There have been some discrepancies from regulatory bodies on which is approved or not, reason we didn’t discuss earlier in our introduction. All comment raised by the reviewer have been inputted in the introduction part of the manuscript (line 77-84).

3. Methods – How were participants recruited? What were the inclusion and exclusion criteria?

We thank reviewer 1 for this comment. The recruitment of participant was using a clearly spelt-out eligibility criteria (see below) and using a convenience sampling from a list of participants who fulfilled the criteria using a CBOs & CSOs drafted list and were willing to write an informed consent, which was carried out in accordance with ethical guidelines of 1975 declaration of Hesinki Declaration of 1975, revised 2000.

Inclusion criteria were being either male or female, aged between 18 and 29, being sexually active, currently a resident of urban or peri urban setting in Nigeria, has ever taken an HIVST and other group who has never taken an HIVST, willing and able to provide verbal oral informed consent, and willing to consent to an audio recorded session.

We have updated the participant selection and recruitment part to reflect the comment being raised (line 125-133).

4. Methods – Please provide a brief description (2-3 sentences) of the journey map methodology along with appropriate citations for the benefit of readers unfamiliar with this approach.

We thank reviewer 1 for this comment. We have updated the method with a journey map section as recommended.

5. Results – It would be helpful to include a table summarizing the demographic characteristics of the 80 participants. Figure 1 does include their geographic distribution, but no figures have been presented. For example, how many men and women were in the sample? What was the age range? How many lived in urban and peri-urban areas?

We thank reviewer 1 for this comment. We have updated the result section with (Table 1) to reflect the gender, age range and geographic distribution.

6 Discussion – Is there a reason why the results might not be subject to social desirability bias?

We thank the reviewer for this comment. We have already reported in our limitations that our study might be subject to social desirability bias, but we try as much to reduce it by using indirect questions, self-completion, the use of proxy users (both the users and non-users), and random sampling from list of participants presented. This have also been updated in the manuscript.

Reviewer #2: The authors should streamline their manuscript to focus on Enablers and Barriers to effective HIV self-testing in Private sector. Currently the manuscript is disorganized with irrelevant information, which doesn't address the enablers/barriers to effective HIVST.

We thank the reviewer 2 for the comment. We have ie

Also, the authors should explicitly describe how was the Journey Map method operationalized in this study so a reader can follow.

We thank reviewer 2 for this comment. This have been reflected in the methodology section by adding a journey map method, how participants were recruited and the inclusion and exclusion criteria.

The author should also highlight what was the role of the private sector in this study. Did the author want to describe the role private health delivery systems?

We thank the reviewer 2 for this comment. We have updated the introduction section to reflect the context of private sector in this study.

The author should use scientific writing, currently the manuscript is full of irrelevant words which doesn't add any value to the paper. The authors should check for grammar and spellings before their next submission.

We thank the reviewer for this comment. We have employed the service of a copy writer and now reflect in the updated manuscript.

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Attachment

Submitted filename: Response to Reviewers.docx

Decision Letter 1

Adetayo Olorunlana

29 Mar 2023

PONE-D-22-23769R1Enablers and Barriers to Effective HIV Self-testing in the Private Sector among Sexually active youths in Nigeria: A Qualitative Study using Journey Map methodologyPLOS ONE

Dear Dr. Hassan Wada,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by May 13 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Adetayo Olorunlana, Ph.D.

Academic Editor

PLOS ONE

Journal Requirements:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #2: All comments have been addressed

Reviewer #3: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #2: Yes

Reviewer #3: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #2: Yes

Reviewer #3: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #2: Yes

Reviewer #3: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #2: Yes

Reviewer #3: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #2: The authors should streamline their manuscript to focus on Enablers and Barriers to effective HIV self-testing in Private sector. Currently the manuscript is disorganized with irrelevant information,which doesn't address the enablers/barriers to effective HIVST. Also the authors should explicitly describe how was the Journey Map method operationalized in this study so a reader can follow. The author should also highlight what was the role of the private sector in this study. Did the author want to describe the role private health delivery systems? The author should use scientific writing, currently the manuscript is full of irrelevant words which doesn't add any value to the paper. The authors should check for grammar and spellings before their next submission.

Reviewer #3: In their present manuscript, the authors have documented factors likely to influence young people's uptake of HIV self-testing in Nigeria through a qualitative approach. The objective is clear and a timely question in the context of HIV prevention in West Africa. The method is appropriate, and the authors have correctly addressed previous reviewer suggestions. Here are a few comments to consider to further strengthen the manuscript:

•The authors should ensure that the paper is formatted according to the COREQ checklist.

Methods:

•Consider moving the “Recruitment and participants selection” section after the “Journey map operation” section.

•Line 121: Describe the HIV prevention stage. Refer to the following articles that describes HIV prevention continuum. A. McNairy, Margaret L, and Wafaa M El-Sadr. “A paradigm shift: focus on the HIV prevention continuum.” Clinical infectious diseases: an official publication of the Infectious Diseases Society of America vol. 59 Suppl 1,Suppl 1 (2014): S12-5. doi:10.1093/cid/ciu251. B. Horn, Tim et al. “Towards an integrated primary and secondary HIV prevention continuum for the United States: a cyclical process model.” Journal of the International AIDS Society vol. 19,1 21263. 17 Nov. 2016, doi:10.7448/IAS.19.1.21263.

•Where was the interview conducted and by whom?

•Include more description about the study setting. Anambra, Kano and Lagos states. Perhaps mention that these states were identified as PEPFAR priority states given evidence of high HIV burden and unmet needs for HIV/AIDS treatment services

•How was data triangulated?

Result

•Consider deleting “The journey map is the process with each stage having its own characteristics using the person’s experience to identify problems and suggest an improvement. However, the person perceives this as a real journey that can be used to improve each stage of HIV self-testing.” This has already bee described in the methods section.

•Line 213 revise to “While the barriers identified at the attracting stage..”

•Line 250, include the dollar equivalence of the naira

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #2: No

Reviewer #3: Yes: Chisom Obiezu-umeh

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Attachment

Submitted filename: PONE-Reviewers comment_BN1.pdf

PLoS One. 2023 Apr 27;18(4):e0285003. doi: 10.1371/journal.pone.0285003.r004

Author response to Decision Letter 1


3 Apr 2023

Society for Family Health,

No. 8 Port Harcourt Crescent

Abuja, Nigeria

March 30th 2023

The Editor-in-Chief,

Editorial Office

PLOS ONE

Dear Editor-in-Chief,

We thank the academic editor and the reviewers for the comments to improve on our manuscript [PONE-D-22-23769]. Please see below our itemized point-by-point responses has been highlighted. Moreover, in the revised manuscript, all changes have been tracked to indicate the revised sections. We would be happy to clarify any aspect of our responses if needed.

Best Regards,

Yusuf H. Wada

Corresponding Author

hwada@sfhnigeria.org

Reviewer #2:

The authors should streamline their manuscript to focus on Enablers and Barriers to effective HIV self-testing in Private sector. Currently the manuscript is disorganized with irrelevant information, which doesn't address the enablers/barriers to effective HIVST. Also, the authors should explicitly describe how was the Journey Map method operationalized in this study so a reader can follow. The author should also highlight what was the role of the private sector in this study. Did the author want to describe the role private health delivery systems? The author should use scientific writing, currently the manuscript is full of irrelevant words which doesn't add any value to the paper. The authors should check for grammar and spellings before their next submission.

We thank the reviewer for this comment. We have reviewed how the Journey map was operationalized (line 112-125), describe the role of private sector in the manuscript, reviewed by a native speaker for irrelevant word and updated the format/logical flow using the COREQ checklist which was adopted from Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. International Journal for Quality in Health Care. 2007. Volume 19, Number 6: pp. 349 – 357 as highlighted by the other reviewer.

Reviewer #3:

In their present manuscript, the authors have documented factors likely to influence young people's uptake of HIV self-testing in Nigeria through a qualitative approach. The objective is clear and a timely question in the context of HIV prevention in West Africa. The method is appropriate, and the authors have correctly addressed previous reviewer suggestions. Here are a few comments to consider to further strengthen the manuscript:

•The authors should ensure that the paper is formatted according to the COREQ checklist.

We thank the reviewer for this comment. We have formatted the manuscript according to the COREQ checklist and updated as appropriate. The COREQ Checklist was adopted from Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. International Journal for Quality in Health Care. 2007. Volume 19, Number 6: pp. 349 – 357.

Methods:

•Consider moving the “Recruitment and participants selection” section after the “Journey map operation” section.

We thank the reviewer for this comment. We have revised as advised with the recruitment and participants selection after the journey map operation section.

•Line 121: Describe the HIV prevention stage. Refer to the following articles that describes HIV prevention continuum. A. McNairy, Margaret L, and Wafaa M El-Sadr. “A paradigm shift: focus on the HIV prevention continuum.” Clinical infectious diseases: an official publication of the Infectious Diseases Society of America vol. 59 Suppl 1,Suppl 1 (2014): S12-5. doi:10.1093/cid/ciu251. B. Horn, Tim et al. “Towards an integrated primary and secondary HIV prevention continuum for the United States: a cyclical process model.” Journal of the International AIDS Society vol. 19,1 21263. 17 Nov. 2016, doi:10.7448/IAS.19.1.21263.

We thank the reviewer for this comment. We have referred to the article and revised as appropriate (see line 126-131 and reference 18-20).

•Where was the interview conducted and by whom?

We thank the reviewer for this comment. We already have that captured in the manuscript (line 157- 162). We have also included a sentence and updated the manuscript on who conducted the interview and by whom.

“The project team from SFH and Busara who were part of the face validity team carried out the qualitative research and collected data in the four dominant language of Nigeria (English, Igbo, Hausa, and Yoruba) using the IDIs and FGDs guides. IDIs were done in English over the phone, while FGDs were conducted in-person for the sexually active youths using the four languages in the three states. We conducted gender-specific FGDs - one FGD was either all men or all women, but we mixed HIVST users and HIVST non-users. During both the IDIs and FGDs, we asked respondents open-ended questions regarding their opinions and perceptions of HIVST, and for IDIs with HIVST users, we asked questions about their past experiences with taking up and using HIVST kits”.

•Include more description about the study setting. Anambra, Kano and Lagos states. Perhaps mention that these states were identified as PEPFAR priority states given evidence of high HIV burden and unmet needs for HIV/AIDS treatment services

We thank the reviewer for this comment. We have included the brief description of the study setting and identify them as PEPFAR priority states and other supporting information as advised (see line 110-117).

•How was data triangulated?

We thank the reviewer for this comment. We have included how the data was triangulated in our manuscript as advised (see line 167-170).

Result

•Consider deleting “The journey map is the process with each stage having its own characteristics using the person’s experience to identify problems and suggest an improvement. However, the person perceives this as a real journey that can be used to improve each stage of HIV self-testing.” This has already been described in the methods section.

We thank the reviewer for this comment. This have been revised and deleted this section.

•Line 213 revise to “While the barriers identified at the attracting stage.”

We thank the reviewer for this comment. We have revised as advised.

•Line 250, include the dollar equivalence of the naira

We thank the reviewer for this comment. We have included the dollar equivalence of the naira (US$ 0.2-2).

Attachment

Submitted filename: Response to reviewers.docx

Decision Letter 2

Adetayo Olorunlana

13 Apr 2023

Enablers and Barriers to Effective HIV Self-testing in the Private Sector among Sexually active youths in Nigeria: A Qualitative Study using Journey Map methodology

PONE-D-22-23769R2

Dear Dr. Hassan Wada,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Adetayo Olorunlana, Ph.D.

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Acceptance letter

Adetayo Olorunlana

17 Apr 2023

PONE-D-22-23769R2

Enablers and Barriers to Effective HIV Self-testing in the Private Sector among Sexually active youths in Nigeria: A Qualitative Study using Journey Map methodology

Dear Dr. Hassan Wada:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Associate Professor Adetayo Olorunlana

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Appendix. IDI guide, sexually active males and females.

    (DOCX)

    S2 Appendix. FGD guide, sexually active males and females.

    (DOCX)

    Attachment

    Submitted filename: Response to Reviewers.docx

    Attachment

    Submitted filename: PONE-Reviewers comment_BN1.pdf

    Attachment

    Submitted filename: Response to reviewers.docx

    Data Availability Statement

    Data cannot be shared publicly because of the nature of the study and national ethical restrictions on data which includes potential identifiable voice and names through the FGDs and IDIs and contain/identify potential sensitive information of the stakeholders, identify HIVST products which have influence on the participants safety. They were also assured that data will only be anonymously analyzed and also shared only on reasonably request as approved on the research protocol. Data are available from Society for Family Health Institutional Data Access for researchers who meet the criteria for access to confidential information through a non-author point of contact email info@sfhnigeria.org or through the corresponding author email hwada@sfhnigeria.org."


    Articles from PLOS ONE are provided here courtesy of PLOS

    RESOURCES